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Statins are used for the primary and secondary prevention of cardiovascular disease by 2 
inhibiting cholesterol synthesis in the liver. Statins have also non-cholesterol-related effects, 3 
called pleiotropic effects, that arise from statins anti-inflammatory, immunomodulatory and 4 
anti-oxidant properties. These effects are especially attractive for the treatment of various 5 
brain diseases ranging from stroke to neurodegenerative diseases. Still, low brain 6 
concentrations after oral drug administration hinder the clinical application of statins in these 7 
pathologies. Pharmaceutical nanotechnologies may offer a solution to this problem, as local 8 
or targeted delivery of nanoencapsulated statins may increase brain availability. This special 9 
report rapidly summarises the potential of statins in the treatment of brain diseases and the 10 
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Statins: a future beyond cholesterol lowering? 28 
In last decades, statins have emerged as one of the most successful class of drug from both a 29 
therapeutic and commercial point of view. In fact, since the approval of lovastatin by FDA in 30 
1987, statins have become the election treatment of hypercholesterolemia leading to 31 
beneficial effects in terms of cardiovascular (CV) risk reduction. Statins have been 32 
demonstrated to be effective in primary prevention and in reducing disease progression with 33 
well-demonstrated improvements in terms of CVD morbidity and mortality [1,2]. The 34 
mechanism of action of statins is the reduction of the liver cholesterol synthesis by 35 
competitively inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 36 
reductase, thus preventing the formation of mevalonic acid, a precursor in the de novo 37 
cholesterol biosynthetic pathway. This induces an increased hepatic expression of low-38 
density lipoprotein (LDL) receptors with subsequent enhanced clearance of circulating LDL-39 
cholesterol. In addition, it has been demonstrated that statins lower triglycerides, although to 40 
a smaller extent and increase high-density lipoprotein (HDL) cholesterol plasma levels [3,4]. 41 
However, some clinical observations related to the rapidity and magnitude of the efficacy in 42 
subgroups of patients have suggested that some cholesterol independent or “pleiotropic” 43 
effects were at play beyond the lipid-lowering actions [4]. These properties have been 44 
explained by the inhibition, via the same mevalonate pathway, of isoprenoid compounds, 45 
such as farnesylpyrophosphate and geranylgeranylpyrophosphate, essential for the post-46 
transcriptional modification and subsequent subcellular localization and intracellular 47 
trafficking of a number of proteins, including signalling GTPase proteins (G proteins), such 48 
as Rho, Ras, Rac, Rap, Ral [5]. These proteins possess a regulatory role in many biochemical 49 
processes and their inhibition, affecting cells regulatory pathways, could be the explanation 50 
of the non-lipid-lowering effects evidenced for statins. 51 
Anti-inflammatory, anti-oxidant and immunomodulatory effects are believed to be the result 52 
of the inhibition of G proteins. In the case of vascular diseases, these actions have been 53 
related to improvement of endothelial function by means of the up-regulation of endothelial 54 
nitric oxide synthase (eNOS), decrease in vascular smooth cell proliferation, reduction in 55 
platelets reactivity and lowering in pro-inflammatory cytokines and reactive oxygen species 56 
(ROS) [6,7]. Finally, statins may hinder leukocyte infiltration of inflamed tissue by blocking 57 
the β2 integrin leukocyte function antigen-1 (LFA-1). However, the actual clinical relevance 58 
of the pleiotropic effects is strongly debated and a clear demonstration of these non-59 
cholesterol related effects appear somewhat elusive [8,9]. 60 
Despite this fact, the significance of the pleiotropic effects of statins appears to emerge from 61 
a number of new indications for which this class of drugs have been proposed [2]. In fact, 62 
many chronic diseases are characterized by dysfunctional inflammatory and/or immune 63 
responses; in this context statins have been proposed as an approach to treat the symptoms of 64 
inflammatory bowel disease [10], rheumatoid arthritis [11] and chronic obstructive pulmonary 65 
disease (COPD) [12]. Furthermore, statins have been shown to have a beneficial effect on 66 
perioperative morbidity and mortality of cardiac, as well as non-cardiac surgery patients, by 67 
reducing major adverse cardiac and cerebrovascular events, but also by possibly reducing 68 
renal injury, respiratory complications and infections [13]. Statins may have also an effect on 69 
the bone favouring the proliferation and differentiation of osteoblast and reducing osteoclasts, 70 
opening an opportunity for their use in the management of osteoporosis. In a recent meta-71 
analysis, it has been evidenced that statins significantly reduce the risk of fracture, improve 72 
bone mineral density and osteocalcin concentrations, especially in male patient subgroups [14]. 73 



































































Finally, a possible chemopreventive/chemotherapeutic role of statins in cancer has attracted a 74 
lot of interest in recent years [15]. Data collected so far are often contradictory and 75 
inconclusive, being based on epidemiological studies with highly heterogeneous cases in 76 
terms of cancer type and statin use. Nevertheless, a recent meta-analysis on statins and 77 
survival in colorectal cancer evidenced a weak improvement in survival associated with statin 78 
use [16], while another study in kidney cancer patients indicated that statin use is associated 79 
with a significantly reduced risk both of cancer-specific and all-cause related mortality [17]. 80 
Pleiotropic effects are regarded however by some authors as controversial and accounting. At 81 
least in part, for the side effects of statins. In fact, inhibiting the mevalonate pathway, statins 82 
not only inhibit cholesterol biosynthesis, but also that of many other products such as 83 
coenzyme Q, selenoproteins and heme A. Muscular adverse effects, ranging from fatigue to 84 
rhabdomyolysis, are the most common side effect of statins, and led in 2001 to the withdraw 85 
from the market of cerivastatin. Hepatotoxicity, neprotoxicity, erectile dysfunction along with 86 
increased risk of developing diabetes mellitus, peripheral neuropathy and autoimmune 87 
diseases are other relevant adverse effects to take into account during statins treatment, even 88 
if in all trials published benefits exceeded all potential risks [18]. 89 
 90 
Potential central nervous systems applications of statins 91 
Some of the most interesting novel potential indications of statins are those related to brain 92 
diseases. Several hurdles, among which the crossing of the blood brain barrier (BBB), 93 
hamper the success of drug therapies having as a target the brain and the central nervous 94 
system (CNS) [19,20]. However, some of the statins, such as simvastatin, atorvastatin, 95 
lovastatin and fluvastatin, are lipophilic in nature and have, in principle, the potential to cross 96 
the BBB [21,22] opening the opportunity for their use for treatment of brain diseases. Their 97 
action at central level could be neuroprotective, a feature that could introduce statins as a new 98 
approach for a range of diseases in which the current therapy is considered unsatisfactory [23]. 99 
The actions of statins in the brain are both cholesterol-dependant and cholesterol-independent 100 
and could be beneficial to a range of CNS disease characterized by a combination of the 101 
following pathophysiological mechanisms: inflammatory reaction, chronic immune 102 
activation, increased production of reactive-oxygen species, cell oxidative damage, altered 103 
neurotransmission, neuronal dysfunction and death, reduced cognitive and memory 104 
performance. 105 
In fact, in addition to the previously mentioned pleiotropic effects, it is suggested that statins 106 
might be able to lower cholesterol levels also in the brain, depleting cholesterol-rich 107 
microdomains in the cell membranes (lipid rafts) and having an impact on neurotransmission, 108 
synaptogenesis and various pathophysiological proteins processing. Statins appear to activate 109 
neuroprotective pathways, such as PKB/Akt, to induce the expression of neurotropic factors, 110 
such as brain-derived neurotrophic factor (BDNF) and even to recruit stem cells [24]. 111 
One of the most straightforward and studied statins application at central level is their 112 
neuroprotective and neurorestorative role in cerebrovascular diseases, such as ischemic and 113 
haemorrhagic stroke. In this sense, statins are considered a preventive treatment of stroke and 114 
of stroke recurrence [25]. In addition, they have a role in acute ischemic stroke therapy: pre- 115 
and post-stroke statin use might reduce stroke severity, functional disability and mortality, 116 
whereas statin withdrawal leads to worse outcomes. This has been attributed to improved 117 
cerebral flow, enhanced fibrinolysis and reduced infarct size related to statin use [26]. 118 



































































The other major interest in the use of statin in the CNS is the increasing epidemiological 119 
evidence of the role they have in the management of neurodegenerative diseases [27]. 120 
Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of 121 
dopaminergic neurons in the substantia nigra, probably as a consequence of 122 
neuroinflammation, oxidative stress and mitochondrial dysfunction. Despite the discordant 123 
results present in literature, a relatively recent meta-analysis of epidemiological studies 124 
correlating statin use to development of the disease indicated a significant reduction in the 125 
risk of PD [28]. The highlighted benefits are possibly due to the cholesterol lowering action, 126 
the reduction of inflammation mediators such as TNF-α, nitric oxide and superoxide and the 127 
modulation of some brain receptors, such as dopamine D1/D2 receptors and NMDA 128 
receptors [27]. 129 
Multiple sclerosis (MS) is an immune-mediated disorder in which CNS resident and invading 130 
immune cells lead to inflammation, oxidative stress, excitotoxicity, demyelination, axonal 131 
degeneration and ultimately neuronal loss. Statins may have a role in the management of MS 132 
via their anti-inflammatory and immunomodulatory actions. In particular, statins action is 133 
mediated by the inhibition of myelin-antigen presentation, of the recruitment of leucocyte 134 
into the CNS and of the activation and differentiation of pro-inflammatory T cells, redirecting 135 
the immunomodulation towards the secretion of anti-inflammatory cytokines (IL-4, IL-5, IL-136 
10, TGF-β) and the suppression of pro-inflammatory signalling (IL-2, IL-12, IFN-γ). Also in 137 
this case, clinical trials with oral statin mono-therapy were only partially effective in showing 138 
effects on MS and some studies have been carried out with combinations of statins and IFN-β 139 
with conflicting results [29]. However, in a recent study high-dose simvastatin treatment has 140 
evidenced a significant reduction in the annualised rate of whole-brain atrophy in patients 141 
affected by secondary progressive MS, for which no satisfactory treatment exists [30].  142 
Recently, the use of statins as a disease-modifying strategy in Alzheimer's disease (AD) has 143 
elicited substantial interest. A series of epidemiological studies had suggested an association 144 
between high blood cholesterol and AD [31]. Subsequent retrospective studies suggested a 145 
decrease in the incidence of AD and dementia for patients who were treated orally with 146 
statins [32]. The effects of statins on AD could be related to several actions: reduction of 147 
cholesterol de novo synthesis in the brain, leading to reduced neurofibrillary tangles and 148 
amyloid β formation; improvement of brain perfusion, reduction of atherosclerosis and 149 
cerebrovascular risk; anti-inflammatory effects and up regulation of eNOS [33]. However, 150 
recent prospective clinical trials in which statins (atorvastatin, simvastatin) have been 151 
administered orally to AD patients were disappointing and failed to provide improvements in 152 
their cognitive status [34]. 153 
Furthermore, statins may have an anti-proliferative, proapoptotic and anti-invasive effect on 154 
brain tumours. Studies on human glioma cells for example are supporting such effects as a 155 
result of proapoptotic effects mediated by lipid raft modulation, Fas translocation and 156 
activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/caspase-3 pathway [35]. This role 157 
has been further supported recently by an epidemiological study in Taiwan that once more 158 
suggests that statins (all statins were considered, i.e. lovastatin, pravastatin, rosuvastatin, 159 
fluvastatin, simvastatin, or atorvastatin) use may reduce the risk of brain cancer [36]. 160 
 161 
Nanomedicines for statins drug delivery to the brain 162 
Despite the clear potential of statins for the treatment of CNS diseases, the clinical evidences 163 
are still limited and sometime even contradictory, with risks of side effects outweighing 164 



































































benefits. Furthermore, beneficial effects have been generally associated with statin high 165 
dosing. These limitations appear as a direct consequence of the pharmacology of statin oral 166 
administration. Despite good absorption, statins undergo a heavy hepatic extraction to low 167 
bioavailability values, with the only exception of rosuvastatin [3]. If we look at lipophilic 168 
statins, considered capable of crossing the BBB, not only the metabolites are more 169 
hydrophilic and then less favoured for BBB crossing, but the unmodified drug shows a high 170 
protein binding. As a consequence that not all statins can cross the BBB, and those which can 171 
might do it at relatively low concentrations [24,37]. 172 
The use of novel and more efficient dosage form able to deliver statins to the brain appear 173 
necessary to advance the use of statins. In particular, nanomedicines are extremely appealing 174 
for this application providing drug encapsulation and protection from chemical and 175 
enzymatic degradation, control of drug release, improved delivery and bioavailability in 176 
particular of poorly-water soluble drugs and targeted distribution in the body [38]. In addition, 177 
the administration of nanoencapsulated statins may contribute to reduce or eliminate 178 
altogether some of the common adverse effects related to statin therapy. 179 
While the literature is rich of nanotechnological approaches for improving statin oral 180 
absorption [39] or their delivery to other body compartments [38], the development of statin 181 
nanomedicines for the treatment of brain diseases is a quite new topic. In fact, the application 182 
of pharmaceutical nanotechnologies for brain delivery is itself an emerging subject in 183 
medicine and only few papers have been published on the delivery to the CNS of 184 
nanoencapsulated statins. The object of this review is to highlight the potential of this 185 
approach and to foster further research in this field. 186 
However, the approaches for using these new formulations in clinical setting appears already 187 
quite well defined: direct local administration to the brain, targeting of the BBB after 188 
intravenous injection and nose-to-brain delivery appear to be the viable options [40]. 189 
Undoubtedly, the most fascinating option is the targeting of the nanocarrier across the BBB 190 
to preferentially distribute the statin into the CNS. In this approach, nanoparticles can be 191 
targeted towards the BBB and/or specific cell types in the CNS. Several proteins and 192 
receptors, such as the transferrin receptor, have been identified on the BBB as potential 193 
targets to improve enhanced nanoparticle uptake and targeting of CNS cells [41]. A specific 194 
delivery appears even more necessary if the therapeutic target are tumoral cells, due to the 195 
necessity of spare as much as possible the healthy tissues surrounding the malignancy [42]. 196 
Generally, nanoparticles have to be administered intravenously, but recently the group led by 197 
Silvia Guterres and Adriana Pohlmann showed nanoparticle accumulation in the CNS even 198 
after oral administration [43].  199 
Additionally, Simsek and collaborators demonstrated the possibility to accumulate 200 
atorvastatin-loaded PLGA-PEG nanoparticles coated with polysorbate 80 in the rat brain. 201 
Nanoparticles produced showed particle size in the range of 30-172 nm and atorvastatin 202 
encapsulation efficiencies up to 50%. Nanoparticles brain accumulation was evaluated by 203 
fluorescent imaging of brain tissues up to 48 hours after IV administration of 15 mg/kg 204 
nanoparticle formulation loaded with the fluorescent marker Nile red. This targeting is based 205 
on the work carried out by Kreuter that attributed to the preferential adsorption in plasma of 206 
apolipoprotein E (ApoE) to the surface of nanoparticles stabilized with polysorbate 80 [44]. 207 
The specific adsorption of ApoE on the nanoparticle corona allows its interaction with the 208 
LDL receptors present on the endothelial cells of the BBB [45]. 209 
In some approaches however, the BBB can be eliminated as a barrier either by direct brain 210 
administration to the brain region affected by the pathology through either surgery or 211 



































































stereotactic injection [46] or by exploiting pathological or deliberate alterations of the BBB 212 
permeability, for example via an osmotic shock or focused ultrasounds [47]. A very recent 213 
research reported the peri-neural injections of lovastatin-loaded PLGA nanoparticles (250-214 
300 nm, drug loading up to 25% w/w on nanoparticle weight). These nanoparticles were used 215 
for assessing nanoencapsulated statin efficacy in an animal model of acute inflammatory 216 
demyelinating polyneuropathy. Nanoparticles loaded with lovastatin administered next to the 217 
sciatic nerve (250 µl single bolus of 20 mg of nanoparticles containing 5 mg of lovastatin) 218 
significantly attenuated the autoimmune neuritis, demonstrating, despite the peripheral nerve 219 
model, that local delivery of nanoparticles is an interesting option for treating autoimmune 220 
diseases possibly also at central level [48]. 221 
An alteration of the BBB can be a consequence of the disease, as in the case of ischemic 222 
stroke. 223 
Campos-Martorell and co-workers evidenced how neutral and negatively charged liposomes, 224 
but not positively charged liposomes of the same size (around 150 nm) accumulated in the 225 
infarcted area of rats undergoing middle cerebral arterial occlusion. Simvastatin administered 226 
intravenously as 1 ml of 6 mg/ml simvastatin-loaded neutral liposomes not only was 227 
accumulated in the infarcted area of ischemic rats but unexpectedly it was delivered and 228 
retained in the brain of sham animals better than the free drug, suggesting a potential 229 
improvement when simvastatin is used as a preventive treatment [49]. 230 
Nasal delivery has been indicated as a possible and convenient way of delivering the drug to 231 
the CNS non-invasively [50,51]. The olfactory region placed in the uppermost part of the nasal 232 
cavity, represent the only part where the CNS is in direct contact with the environment and 233 
may represent a route to bypass the BBB to gain access to the brain. However, the 234 
administration of statins via the nasal route is challenging due to the poor water solubility of 235 
these drugs and the barrier effect provided by mucus. Nanoparticles could favour the nose-to-236 
brain delivery by favouring mucus and/or adhesion, providing penetration enhancement 237 
through the nasal mucosa or via targeting of the olfactory neurons. 238 
A recent study of our group proposed the use of lecithin/chitosan nanoparticles loaded with 239 
simvastatin able to be biodegraded by the enzymes present in the nasal secretions. In 240 
preliminary gamma scintigraphy studies in rats, technetium (Tc99m) labelled nanoparticles 241 
(200 nm, 1 mg/ml simvastatin), but not a suspension of the drug or the radiolabel alone, 242 
where able to increase the radioactivity detected in the brain of the animals after the nasal 243 
instillation of 10 µl of the nanoparticle formulation in each nostril of the animals [52]. 244 
 245 
Future Perspectives 246 
Statins are emerging with a range of possible applications for the treatment of a number of 247 
brain and CNS diseases. It appears clear that the pharmacokinetics and pharmacodynamics of 248 
this class of drugs do not allow for a real role in these new indications to the traditional oral 249 
statins administration. Nanotechnology-enabled formulations, in this case more than in many 250 
others, could provide a clinical advantage over classic formulation. In fact, nanocarriers 251 
appear to be pivotal for the protection, the targeting and the delivery of statins to the brain 252 
through local, intravenous and nasal delivery. The relevance of each clinical approach using 253 
the nanomedicines will be closely related to the disease to be treated, to this regards acute 254 
diseases would probably require local delivery or intravenous administration, while chronic 255 
diseases should be addressed with targeted approaches or via nasal delivery, to limit the 256 
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Statins: a future beyond cholesterol lowering? 263 
• Statins block liver cholesterol synthesis by inhibiting the enzyme 3-hydroxy-3-264 
methylglutaryl-coenzyme A (HMG-CoA) reductase 265 
• Through the same pathway however statins inhibit the product isoprenoids involved 266 
in the post-transcriptional modification of proteins 267 
• Signalling GTPase proteins (G proteins), such as Rho, Ras, Rac, Rap, Ral are affected 268 
leading to “pleiotropic” effects 269 
• Pleiotropic effects of statins include anti-inflammatory, immunomodulatory and anti-270 
oxidant  271 
• Statins may hinder leukocyte infiltration of inflamed tissue by blocking the β2 272 
integrin leukocyte function antigen-1 (LFA-1) 273 
 274 
Potential central nervous systems applications of statins 275 
• Statins have the potential to be beneficial in brain diseases 276 
• In stroke statins may improve cerebral flow, enhance fibrinolysis and reduce infarct 277 
size 278 
• Statins may reduce Parkinson’s disease risk via the cholesterol lowering action, the 279 
reduction of inflammation mediators and the modulation of some brain receptors 280 
• In Multiple Sclerosis statins may have a role reducing myelin-antigen presentation, 281 
leucocytes recruitment and pro-inflammatory signalling 282 
• Several effects appear to be beneficial in Alzheimer’s disease, such as inhibition of 283 
neurofibrillary tangles and amyloid β formation, improvement of brain perfusion and 284 
anti-inflammatory effects 285 
• Despite lipophilic statins may cross the BBB, first pass metabolism and low CNS 286 
concentrations hinder statins use in brain diseases 287 
 288 
Nanomedicines for the drug delivery to the brain 289 
• Pharmaceutical nanotechnologies may enable the use of statin in the brain 290 
• Nanomedicines can improve drug solubility, to protect the active substance from 291 
chemical or enzymatic degradation, to provide controlled and/or targeted delivery, to 292 
favour the crossing of the biological barriers and ultimately improve brain availability 293 
• Local invasive delivery, targeting and crossing of the BBB and nose-to brain delivery 294 
appear as the main route for using clinically nanoencapsulated statins 295 
 296 
Future perspectives 297 
• Not many studies have explored the use of nanoencapsulated studies for brain 298 
diseases 299 
• The potential of these innovative formulations is high as traditional administration 300 
does not appear to be clinically effective for CNS indications 301 
• The clinical use of nanoencapsulated statins for brain diseases has to be carefully 302 
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